Human albumin solution for resuscitation and volume expansion in critically ill patients (Review)
The
A B S T R A C T

Background
Human albumin solutions are used in a range of medical and surgical problems. Licensed indications are the emergency treatment of shock and other conditions where restoration of blood volume is urgent, burns, and hypoproteinaemia. Human albumin solutions are more expensive than other colloids and crystalloids.
Objectives
To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in the management of critically ill patients.
Search strategy
We searched the Cochrane Injuries Group trials register, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and BIDS Index to Scientific and Technical Proceedings. Reference lists of trials and review articles were checked, and authors of identified trials were contacted. The search was last updated in August 2004.
Selection criteria
Randomised controlled trials comparing albumin/PPF with no albumin/PPF, or with a crystalloid solution, in critically ill patients with hypovolaemia, burns or hypoalbuminaemia.
Data collection and analysis
We collected data on the participants, albumin solution used, mortality at the end of follow up, and quality of allocation concealment. Analysis was stratified according to patient type.
Main results
We found 32 trials meeting the inclusion criteria and reporting death as an outcome. There were 1632 deaths among 8452 trial participants.
For hypovolaemia, the relative risk of death following albumin administration was 1.01 (95% confidence interval 0.92, 1.10). This estimate was heavily influenced by the results of the SAFE trial which contributed 91% of the information (based on the weights in the meta-analysis). For burns, the relative risk was 2. 40 (1.11, 5.19 ) and for hypoalbuminaemia the relative risk was 1.38 (0.94, 2.03). There was no substantial heterogeneity between the trials in the various categories (chi-square = 21.86, df = 25, p =0.64) . The pooled relative risk of death with albumin administration was 1.04 (0.95, 1.13).
Authors' conclusions
For patients with hypovolaemia there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia. The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and adequately powered randomised controlled trial.
P L A I N L A N G U A G E S U M M A R Y
There is no evidence that giving human albumin to replace lost blood in critically ill or injured people improves survival when compared to giving saline.
Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein), is used to help restore blood volume and hopefully reduce the risk of dying. Blood products (including human albumin), non-blood products or combinations can be used. The review of trials found no evidence that albumin reduces the risk of dying. Albumin is very expensive in which case it may be better to use cheaper alternatives such as saline for fluid resuscitation.
B A C K G R O U N D
In patients with acute and chronic illness, serum albumin concentration is inversely related to mortality risk. A systematic review of cohort studies meeting specified criteria estimated that, for each 2.5 g/L decrement in serum albumin concentration, the risk of death increases by between 24% and 56% (Goldwasser 1997) . The association persists after adjusting for other known risk factors and pre-existing illness, suggesting a direct protective effect of the albumin molecule (Goldwasser 1997) . Largely as a result of these observations, human albumin solutions are now used in the management of a diverse range of medical and surgical problems. Published indications for human albumin solution include the emergency treatment of shock and other conditions where restoration of blood volume is urgent, the acute management of burns, and clinical situations associated with hypoproteinaemia (ABPI 1998).
In comparison with other colloidal solutions and with crystalloid solutions, human albumin solutions are expensive (McClelland 1990) . Volume for volume human albumin solution is twice as expensive as hydroxyethyl starch, and over thirty times more expensive than crystalloid solutions such as sodium chloride or Ringer's lactate. Because of the high cost and limited availability of human albumin, it is particularly important that its use should be restricted to the indications for which it has shown to be effective. To assess the effectiveness and safety of human albumin solutions in the management of critically ill patients, particularly those with hypovolaemia from injury or surgery, burns and hypoproteinaemia, a systematic review of randomised controlled trials was conducted.
O B J E C T I V E S
To quantify the effect on mortality of human albumin administration in the management of critically ill patients.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W
Types of studies
We sought to identify all randomised controlled trials of human albumin or plasma protein fraction (PPF) administration (albumin/PPF versus no albumin/PPF, or a crystalloid solution).
Types of participants
Critically ill patients with hypovolaemia, burns or hypoproteinaemia. Trials involving patients receiving pre-operative volume loading or haemodilution, and trials of albumin administration during paracentesis, were excluded.
Types of intervention
Human albumin solution or plasma protein fraction (PPF).
Types of outcome measures
The principal outcome measure was mortality from all causes assessed at the end of the follow up period scheduled for each trial.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: Injuries Group methods used in reviews. #1 explode "Fluid Therapy" / all SUBHEADINGS #2 explode "Albumins" / all SUBHEADINGS #3 explode "Plasma Substitutes" / all SUBHEADINGS #4 explode "Saline Solution Isotonic" / all SUBHEADINGS #5 explode "Isotonic Solutions" / all SUBHEADINGS #6 explode "Colloids" / all SUBHEADINGS #7 colloid* or albumin* or dextran* or gelatin* or gentran* or h?emaccel* or pentastarch* or pentaspan* or hetastarch* #8 crystalloid* or ringer* or hartman* or sodium* or potassium* or salin* #9 ppf or (plasma next protein*) #10 (fluid near therap*) or (fluid near restor*) or (fluid near substitut*) or (fluid near resuscitat*) or (fluid near replac*) #11 (volume near therap*) or (volume near restor*) or (volume near substitut*) or (volume near resuscitat*) or (volume near replac*) 
M E T H O D S O F T H E R E V I E W
One reviewer (a different person for different databases) scanned the titles and abstracts of reports identified by electronic searching to produce a list of possibly relevant reports. Two reviewers (PA and IR) then checked this list to determine which articles to retrieve in full. Disagreements were resolved by discussion.
The same two reviewers then applied the selection criteria, again resolving disagreements by discussion. They then both extracted data on study design, allocation concealment, participants, interventions and mortality. One reviewer (IR) put the data into Review Manager while the other (PA) checked it against his data extraction.
Where clarification on any aspect of the study was needed one reviewer sought to contact the author of the trial.
Relative risks and 95% confidence intervals for mortality were calculated for each trial on an intention to treat basis. Heterogeneity between trials was tested using a Chi-squared test, where p less than or equal to 0.05 was taken to indicate significant heterogeneity. As long as statistical heterogeneity did not exist, for dichotomous data, summary relative risks and 95% confidence intervals were calculated using a fixed effects model. In the event of statistical heterogeneity, if the source of heterogeneity could obviously be related to patient type, or allocation concealment, we stratified the analyses on that dimension.
D E S C R I P T I O N O F S T U D I E S
A total of 37 randomised controlled trials were identified that met the study inclusion criteria. Mortality data were available either from the published report or on contact with the authors of 32 of these trials. The five trials for which mortality data could not be obtained (McNulty 1993; Skillman 1975; Ernest 1999; Ernest 2001; Oca 1999 ) included a total of 124 randomised patients, comprising 8% of the total number of randomised patients in all trials meeting the study inclusion criteria. One of the trials was an unpublished trial registered in the Medical Editors' Trial Amnesty. Further details about this trial, including data on mortality, were obtained directly from the trialist. In six trials there were no deaths in either the intervention or comparison groups. The trial by Lucas et al was reported in five publications. An early report gave the mortality data for 52 randomised patients, 27 allocated to receive albumin, 25 allocated to receive no albumin (Lucas 1978) . Subsequent publications indicated that recruitment to the trial continued until 94 patients were randomised. Mortality data for all the 94 patients were not published, nor were they available on contact with the author. Consequently the outcome data for the 52 patients are presented. For the 25 included trials in which there were one or more deaths in either the intervention or control groups, allocation concealment involved a method that would be expected to reduce the risk of foreknowledge of treatment allocation (pharmacy controlled randomisation or serially numbered sealed opaque envelopes) in 13 trials, was unclear in eight trials, and inadequate in four trials.
M E T H O D O L O G I C A L Q U A L I T Y
Bland 1973
Randomised control trial. Therapy cards were randomised in pairs matched for weight. Method of allocation concealment was not described.
Bland 1976
This study is reported as randomised but the method of allocating random numbers and method of allocation concealment are unknown.
Boldt 1993
Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes.
Boutros 1979
The study is reported as randomised but the method of randomisation and allocation concealment are unknown.
Brown 1988
The random sequence was generated using random number tables. No allocation concealment.
Ernest 1999
Randomisation was done by the hospital chart number (odd/even).
Ernest 2001
Randomisation was done by the hospital record number (odd/even).
Foley 1990
Patients were randomly assigned to either a treatment or non treatment group by medical record number.
Gallagher 1985
Randomisation and allocation concealment were by computerised system.
Golub 1994
Random sequence was computer generated. Allocation concealment was by the use of sealed opaque envelopes.
Goodwin 1983
Randomisation was according to random number tables. The methods of allocation concealment were unknown.
Greenhalgh 1995 Randomisation scheme controlled by the pharmacy Greenough 1993 Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes.
Grundmann 1982
The study is reported as prospectively randomised, but the methods of randomisation and allocation concealment are unknown.
Jelenko 1978
Kanarek 1992
Lowe 1977
The method of allocating random numbers is unknown. Sealed envelopes were used to ensure allocation concealment.
Lucas 1978
Allocation was based on the last digit of each patient's case number. Ninety four patients were randomised in total but the number of deaths was not reported in the final report. However, in a preliminary report, based on 52 of the randomised patients, deaths were reported.
McNulty 1993
Nielsen 1985
This study is reported as randomised but the method of allocation concealment is not described.
Nilsson 1980
Oca 1999
Randomisation was done by sequentially numbered, sealed, opaque envelopes.
Pockaj 1994
Prien 1990
Rackow 1983
Randomisation was according to a pre-determined randomisation schedule, but the methods and the allocation concealment are unknown.
Rubin 1997
Allocation concealment was by a sealed opaque envelope system in the hospital pharmacy.
SAFE 2004
Central randomisation accessed on the internet through a secure website with use of a minimisation algorithm. Blinding was assured through the use of specially designed masking cartons and specially designed and manufactured administration sets. The authors report that the effectiveness of the blinding was confirmed in a formal study before the trial was initiated.
Shah 1977
Randomised controlled trial. Allocation by sealed envelope.
Skillman 1975
So 1997
Randomised controlled trial. Allocation concealment was by computerised system.
Tollofsrud 1995
The method of generating random numbers is unknown. Allocation concealment was by sealed opaque envelopes.
Virgilio 1979
Randomisation was determined using random number tables. Methods of allocation concealment are unknown.
Woittiez 1998
Wojtysiak 1992
Randomisation was determined using random number tables. Allocation concealment was inadequate.
Woods 1993
Patients with even hospital numbers were allocated to the group receiving albumin, while those with odd hospital numbers were allocated to the group not receiving supplemental albumin.
Zetterstrom 1981a
Patients were randomly divided into two groups. Allocation concealment was by the use of sealed opaque envelopes.
Zetterstrom 1981b
R E S U L T S
For hypovolaemia the pooled relative risk of death following albumin administration was 1.01 (95% confidence interval 0.92, 1.10). This estimate was heavily influenced by the results of the SAFE trial which received 91% of the weight. For burns the relative risk was 2.40 (1.11, 5.19), and for hypoalbuminaemia the relative risk was 1.38 (0.94, 2.03). There was no substantial heterogeneity between the trials in the various categories (chi-square = 21.86, df = 25, p =0.64). The pooled relative risk of death with albumin administration was 1.04 (0.95, 1.13).
D I S C U S S I O N
There is no evidence that albumin reduces mortality in patients with hypovolaemia, burns and hypoproteinaemia. For patients with burns and hypoproteinaemia, there is a suggestion that albumin administration may increase mortality.
Mortality was selected as the outcome measure in this systematic review for several reasons. In the context of critical illness, death or survival is a clinically relevant outcome that is of immediate importance to patients, and data on death are reported in nearly all studies. Furthermore, one might expect that mortality data would be less prone to measurement error or biased reporting than would data on pathophysiological outcomes. The use of a pathophysiological end-point as a surrogate for an adverse outcome assumes a direct relationship between the two, an assumption that may sometimes be inappropriate. Finally, when trials collect data on a number of physiological end points, there is the potential for bias due to the selective publication of end points showing striking treatment effects. Because we obtained mortality data for all but four of the included trials, the likelihood of bias due to selective publication of trial outcomes is minimal.
Although publication bias is a potent threat to the validity of systematic reviews, it is unlikely to have had an important impact in this study. There was no evidence of funnel plot asymmetry on visual inspection. In some of the trials included in this review, allocation concealment was inadequate or was unclear. As a result, it is possible that more severely ill patients were preferentially allocated to the albumin treated group which may account for the increased mortality risk in this group. Nevertheless, when the analyses were repeated, including only those trials in which allocation concealment involved a method that would be expected to reduce the risk of foreknowledge of treatment allocation, the point estimates were little different.
Because many of the trials included in this meta-analysis are small and many are poorly concealed, the results must be interpreted with caution. The SAFE trial, however, is a notable exception. The SAFE trial included a total of 6997 randomised participants, allocation was well concealed, the use of a minimisation algorithm helped to ensure that baseline characteristics were well balanced, vigorous attempts were made to ensure that the participating clinicans were blind to the type of fluid that was administered, and an intention-to-treat analysis was undertaken. The SAFE trial provided no evidence that albumin reduced mortality in patients with hypovolaemia, although the possibility of a modest benefit or harm could not be excluded.
This systematic review was first updated in November 2001. One additional trial was identified and included (Bland 1973) . This trial compared albumin and dextrose infusions in new-born infants with low cord serum protein levels who were considered to be at risk of respiratory distress. This trial meets the eligibility criteria for the review (hypo-proteinaemia) but had been overlooked in the original search. However, the inclusion of this trial does not change the conclusions of the review. The review was most recently updated in August 2004, following the publication of the SAFE trial.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
For patients with hypovolaemia there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia and a suggestion that albumin may increase the risk of death.
Implications for research
The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonably that albumin should only be used within the context of well concealed and adequately powered randomised controlled trial.
N O T E S
Please note that this review was also published in the BMJ 1998;317:235-240.
F E E D B A C K
Human albumin solution Summary 1. It would be helpful to state that this review was published in the BMJ in 1998, to summarise the subsequent correspondence in print and on the BMJ website, and to note the respects (if any) in which this Cochrane review differs from the BMJ publication. 2. It would be valuable to summarise the report of the Committee for Safety of Medicines (CSM) on this review in the Comments and Criticisms section, with a rejoinder by the authors. 3. Because mortality was not the primary endpoint in any of the trials reviewed, it would be useful to note the primary outcomes of each trial, under 'characteristics of included trials'. 4. It would be helpful if the number of participants in each arm of each reviewed trial appeared under 'characteristics of included trials.' Author's reply 1. We agree that it is important to direct the reader to other published versions of the review and will ensure that readers are alerted to the BMJ publication. We do not think it is appropriate to summarise the correspondence in response to this review, as to do so would run the risk of misrepresenting the views of the correspondents. At the time of first publication the Cochrane review was identical to the review published in the BMJ. However, the Cochrane review will be regularly updated to take account of new information from randomised controlled trials. 2. The Cochrane Database of Systematic Reviews is an international database and for this reason we believe that it would be inappropriate to give undue emphasis to the deliberations of the British Committee on Safety of Medicines (CSM). 3. Mortality was recorded in all but two of the trials included in our systematic review. However, we have no information on whether this was considered by the trialist to be the primary endpoint and would be interested to hear where the author of the comment found this information. How does the author of the comment define a primary endpoint? The concept of a primary endpoint implies a selection within the mind of the trialist of the most important endpoint. We would also ask whether it is appropriate that a process within the mind of a trialist should impact importantly on the estimation of the effect of albumin on mortality, and if so, what is the scientific basis for this. 2. The Cochrane Albumin Review excluded or omitted extensive randomised controlled trials' evidence in the three categories of indications, namely, hypovolaemia, burns and hypoalbuminaemia(2) and this excluded and omitted evidence indicated that albumin may reduce rather than increase mortality.
(1) Horsey P Albumin and hypovolaemia -is the Cochrane evidence to be trusted? Lancet 2002 359 70-72 (2) Willkes MM and Navickis RJ Patient survival after human albumin administration: a meta-analysis of randomised controlled trials.
Annals of Internal Medicine 2001 135 149-164
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.
Author's reply
We are grateful to Dr Horsey for his thoughtful comments on our systematic review of albumin administration in critically ill patients. The comments were first made as a commentary in The Lancet (2002;359:70-72) . Our response to these comments was published in the same issue (Lancet 2002:359:72-3) . We are pleased that this discussion will now be available to readers of the Cochrane Library.
Dr Horsey feels that some of the trials included under the category 'hypovolaemia' would be more appropriate in a different category. We accept that in some clinical situations hypovolaemia and hypoalbuminaemia co-exist so that deciding which category would be most appropriate is a matter for judgement. Also, as Dr Horesy points out, the relationship between hypovolaemia and low blood pressure can be complicated, and the presence of the latter might not always signify the former. Nevertheless, our judgements about the categories were made without knowledge of the results of the trials and we are reluctant to change these post-hoc.
We are grateful to Dr Horsey for drawing our attention to the meta-analysis by Wilkes et al that was funded by the Plasma Protein Therapeutics Association. Because the inclusion criteria for the Cochrane Injuries Group Albumin Reviewer and the Wilkes reviews are different it does not follow that the two reviews should include the same trials.
We are pleased that our systematic review has stimulated so much interest from the intensive care community. However, it is a cause for concern that four years following the publication of our review, in which we concluded that there is no evidence that albumin administration reduced mortality in critically ill patients and a suggestion that it may increase mortality, that albumin continues to be used and promoted. Hopefully, the SAFE trial (www.safestudy. net) will provide the evidence needed to resolve this issue Contributors Comment: Dr PJ Horsey Reply: Professor Ian Roberts
P O T E N T I A L C O N F L I C T O F I N T E R E S T
None known.
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R E F E R E N C E S
Participants
Newborn infants considered at high risk for developing respiratory distress. Those with a cord serum protein level less than 4.6g/100ml and at least one of the following; birthweight less than 2500g, gestational age less than 37 weeks, arterial pH less than 7.25. 
Allocation concealment C
Study Foley 1990
Methods Patients were randomly assigned to either a treatment or non-treatment group by medical record number.
Participants Hypoalbuminaemic (serum albumin <25g/L) critically ill patients. Potential subjects with Child's class C cirrhosis were excluded. Interventions 1) The treatment group (n=18) received 25-50g per day of 25% albumin in addition to full nutritional support with parenteral nutrition. Albumin administration was continued daily until serum albumin levels exceeded 25 g/L after which patients received additional albumin as needed to keep the albumin level at 25 g/L or higher.
2) The non treatment group (n=22) received no exogenous concentrated albumin.
Outcomes Deaths reported.
Notes Follow up to discharge.
Allocation concealment C
Study Gallagher 1985
Methods Randomised controlled trial. Method of allocation concealment not described. Author contacted -allocation concealment by computerised system -patient details were entered before treatment assignment was revealed.
Participants
Patients after coronary artery bypass graft surgery. Interventions 1) The treatment group (n=116) received 37.5g/day of albumin until the circulating albumin concentration increased to 3.0g/dL.
2) The control group received no supplemental albumin. Both groups received standard nutritional support.
Outcomes
Deaths reported.
Notes
Follow-up to discharge.
Allocation concealment A
Study Goodwin 1983
Methods Randomised controlled trial. Method of allocation concealment not described. Participants 79 thermally injured patients. No other inclusion criteria were reported. All of the participants were previously healthy young adults.
Interventions 1) The treatment group (n=40) group received 2.5% albumin in Ringer's lactate 2) The control group (n=39) Ringers lactate. Allocated fluid was used throughout resuscitation.
Outcomes
Notes
Allocation concealment B
Study Greenhalgh 1995
Methods
Method of random allocation not described. Author contacted and confirmed the use of a randomisation scheme controlled by the pharmacy.
Participants
Patients aged 18 years or younger with acute burns.
Interventions 1) High albumin group (n=34): Patients were supplemented with human albumin to maintain serum levels between 2.5 and 3.5g/dL. Albumin was supplied as a continuous drip of 25% human albumin at a rate of 3-10mL/hour. Supplementation was discontinued if serum albumin levels remained >2.5 g/dL without supplementation or if intravenous support was discontinued.
2) Low albumin group (n=36): Patients were not given albumin supplementation unless levels dropped <1.5 g/dL. During burn shock, patients were allowed to receive albumin if they had levels <2.0 g/dL and were receiving >4 mL/Kg/% burn fluid resuscitation.
Outcomes
Notes Follow-up to discharge.
Allocation concealment A
Study Greenough 1993
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes.
Participants
Infants between 24 and 34 weeks gestational age, who were ventilator dependent, and had a serum albumin level of less than or equal to 30g/l.
Interventions 1)Intervention group (n=20) received 5ml/kg 20% salt-poor human albumin.
2) Control group (n=20) received 5ml/kg of the infant's maintainance fluids.
Outcomes
Deaths were not reported. Author contacted and provided data on deaths.
Notes Follow-up to 24 hours after infusion.
Allocation concealment A
Study Grundmann 1982
Methods Randomised controlled trial. Method of allocation concealment not fully described.
Participants
Participants were undergoing partial gastrectomy. The average age was 50 years (range 19-84).
Interventions 1) Intervention group (n=14) group received human albumin 2) Control group (n=6) details of crystalloid were not reported. Allocated fluid was continued for 4 days after operation.
Outcomes
Notes
Allocation concealment B
Study Jelenko 1978
Methods Randomised controlled trial. Method of allocation concealment not described. Participants Participants had burns covering more than 20% of body surface. Interventions 1) Intervention group (n=27) received supplemental salt-poor albumin totalling a maximum of 150g during operation and 150g per day over the next five days.
2) Control group (n=25) received standard resuscitation regimen but no supplemental albumin.
Outcomes Deaths reported.
Notes
In the final report of 94 randomised patients deaths were not reported. However, in this preliminary report of 52 injured patients deaths were reported.
Allocation concealment C
Study McNulty 1993
Methods Randomised controlled trial. Method of allocation concealment not described. Participants
Patients following elective cardiopulmonary bypass.
Interventions 1)Intervention group (n=14) received 5% albumin. 2)Control group (n=14) received isotonic crystalloid.
Outcomes
Deaths not reported.
Notes
Length of follow-up unspecified.
Allocation concealment B
Study Nielsen 1985
Methods Randomized controlled trial. Method of allocation concealment not described. Participants
Patients admitted for reconstructive surgery of the abdominal aorta. Twenty six patients were randomised. Allocation concealment B
Study Rackow 1983
Participants were above 18 years of age, and had any one of the following pre-determined indicators of shock: systolic blood pressure of 90mmHg or less, a cardiac index of less than 2.2L./min.m2, a serum arterial lactate greater than 18mg/dl and WP less than 15mmHg.
Interventions 1)Intervention group ( n= 9) received 5% albumin 2) Control group (n=8) received 0.9% NaCl. Allocated fluid was given as needed until the end of resuscitation.
Outcomes
Notes
Allocation concealment B
Study Rubin 1997
Methods Patients were randomised using "a closed envelope system in the pharmacy".
Participants
Patients with hypoalbuminaemia (<2.5g/dL) who required TPN for at least six days, were not pregnant or under age, and did not have metastatic cancer, cirrhosis, or nephrotic syndrome.
Interventions 1) Intervention group (n=16) 25g on normal serum albumin 2) Control group (n=15) 100 mL of normal saline placebo over a 1 hour period daily.
Allocation concealment A
Study
SAFE 2004
Methods Central randomisation accessed on the internet through a secure website with use of a minimisation algorithm.
Blinding was assured through the use of specially designed masking cartons and specially designed and manufactured administration sets. The authors report that the effectiveness of the blinding was confirmed in a formal study before the trial was initiated.
Participants
Patients 18 years of age or older admitted to ICU who the treating clinician judged to require fluid administration to maintain or increase intravascular volume, with this decision supported by the fulfillment of at least one objective criterion. Patients admitted after cardiac surgery, after liver transplantation, or for the treatment of burns were excluded. Interventions 1) 4% Albumin or 2) Normal saline
The allocated study treatment was used for all fluid resuscitation in the ICU until death or discharge or until 28 days after randomisation. The treating clinicians determined the amount and rate of fluid administration according to each patient's clinical status and response to treatment. 
Outcomes
Allocation concealment C
Study Woods 1993
Methods Randomised controlled trial. Patients with even hospital numbers were randomised to the group receiving albumin while those patients with odd hospital numbers were randomised to the group not receiving supplemental albumin.
Participants
Patients undergoing surgery for abdominal aortic aneurysm, aortoiliac or aortofemoral bypass.
Interventions 1) Intervention group (n=37): albumin was replaced to a level greater than or equal to 3.5 g/dL.
2) Control group (n=32): received no supplemental albumin.
Outcomes
Allocation concealment C
Study
Zetterstrom 1981a
Methods The patients were randomly divided into two groups. The method of allocation concealment is not described. Author was contacted and confirmed the use of sealed opaque envelopes.
Participants
Adult patients undergoing elective major abdominal surgery.
Interventions 1) Intervention group (n=15) 2) Control group (n=15) A similar schedule of fluid therapy and blood replacement was followed in the intervention and control groups. However, the albumin group received a 20% solution of human albumin intravenously according to the following scheme: At the end of the operation: 100ml. Postoperatively on the day of the operation: 200-300 ml. 
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